Clinical Trials Browser

Mesothelioma, Malignant × Brentuximab Vedotin × 1 year × Clear all

NCT03007030 2025-11-10

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant